Intermediates for and synthesis of 3-methylene cephams
    1.
    发明授权
    Intermediates for and synthesis of 3-methylene cephams 失效
    3-亚甲基cephams的中间体和合成

    公开(公告)号:US06683176B2

    公开(公告)日:2004-01-27

    申请号:US09958857

    申请日:2001-12-31

    IPC分类号: C07D50122

    摘要: The present invention relates to novel processes for the preparation of 3-methylenecephams. More specifically, the present invention relates to the intramolecular cyclization of penicillin sulfoxide derived monocyclic azetidinone derivatives with organometallic catalysts of the formula III. MEx(H2O)y  (III) wherein: M is Sc, Y, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Zr, Hf, Th, Nb, Ta, U, Bi, or In; E is O[SO2(C1-C6 polyfluoroalkyl)], N[SO2(C1-C6 polyfluoroalkyl)]2, or C[SO2(C1-C6 polyfluoroalkyl)]3; x is 3; y is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9.

    摘要翻译: 本发明涉及制备3-亚甲基脑炎的新方法。 更具体地说,本发明涉及由式III的有机金属催化剂衍生的青霉素亚砜衍生的单环氮杂环丁酮衍生物的分子内环化,其中M为Sc,Y,La,Ce,Pr,Nd,Sm,Eu,Gd,Tb, Dy,Ho,Er,Tm,Yb,Lu,Zr,Hf,Th,Nb,Ta,U,Bi或In; E是O [SO2(C1-C6多氟烷基)],N [SO2(C1-C6多氟烷基 )] 2或C [SO 2(C 1 -C 6多氟烷基)] 3; x为3; y为0,1,2,3,4,5,6,7,8或9。

    Intermediates for 3-aminoazetidin-2-ones
    3.
    发明授权
    Intermediates for 3-aminoazetidin-2-ones 失效
    3-氨基氮杂环丁烷-2-酮的中间体

    公开(公告)号:US4226767A

    公开(公告)日:1980-10-07

    申请号:US41281

    申请日:1979-05-21

    CPC分类号: C07D205/085

    摘要: 1-[.alpha.-(Carboxy)-4-hydroxybenzyl]-3.beta.-aminoazetidin-2-one esters are prepared by converting 2-acyl-3,3-dialkyl-7-oxo-.alpha.-[4-(benzyloxy)phenyl]-4-thia-2,6-diazabicyclo[3.2.0]heptane-6-acetic acid esters with mercuric acetate in an aqueous organic solvent mixture, e.g., in aqueous methanol, to 7-oxo-3-phenyl-.alpha.-[4-(benzyloxy)phenyl]-4-oxa-2,6-diazabicyclo[3.2.0]hept-2-ene-1-acetic acid esters and the latter are reacted with PCl.sub.5 and pyridine to provide the monocyclic 1-[.alpha.-(carboxy)-4-benzyloxybenzyl]-3.beta.-(.alpha.-chlorobenzylideneamino)-4-chloroazetidin-2-one esters. Reduction of the dichloro azetidin-2-one with an organo tin hydride and azobisisobutyronitrile affords the deschloro, 1-[.alpha.-(carboxy)-4-benzyloxybenzyl]-3.beta.-benzylideneaminoazetidin-2-one ester. The latter is hydrolyzed and the benzyloxy group is cleaved via catalytic hydrogenolysis to yield an ester of 1-[.alpha.-(carboxy)-4-hydroxybenzyl]-3.beta.-aminoazetidin-2-one. The 3.beta.-amino ester is useful for the preparation of the antibiotic FR 1923 (nocardicin).

    摘要翻译: 通过将2-酰基-3,3-二烷基-7-氧代-α-[4-(苄氧基)苯基 ] -4-硫杂-2,6-二氮杂双环[3.2.0]庚烷-6-乙酸酯与乙酸汞在含水有机溶剂混合物(例如甲醇水溶液)中加入到7-氧代-3-苯基-α- [4-(苄氧基)苯基] -4-氧杂-2,6-二氮杂双环[3.2.0]庚-2-烯-1-乙酸酯,后者与PCl5和吡啶反应,得到单环1- [ α - (羧基)-4-苄氧基苄基]-3β-(α-氯亚苄基氨基)-4-氯氮杂环丁-2-酮酯。 用有机锡氢化物和偶氮二异丁腈还原二氯氮杂环丁烷-2-酮,得到脱氯,1- [α-(羧基)-4-苄氧基苄基]-3β-亚苄基氨基氮杂环丁-2-酮酯。 将后者水解并通过催化氢解裂解苄氧基,得到1- [α-(羧基)-4-羟基苄基]-3β-氨基吖丁啶-2-酮的酯。 3β-氨基酯可用于制备抗生素FR1923(诺卡霉素)。

    Process for antibiotic FR 1923 and related compounds
    4.
    发明授权
    Process for antibiotic FR 1923 and related compounds 失效
    抗生素FR1923及相关化合物的制备方法

    公开(公告)号:US4158004A

    公开(公告)日:1979-06-12

    申请号:US739161

    申请日:1976-11-05

    摘要: Process for 1-[.alpha.-(carboxy)-4-hydroxy or protected-hydroxybenzyl]-3-acylamidoazetidin-2-one esters, useful intermediates for preparing antibiotic FR 1923, comprising the ring opening of a 2-acyl-3,3-dialkyl-7-oxo-.alpha.-[4-(protected-hydroxyphenyl]-4-thia-2,6-diazabicyclo[3.2.0]heptane-6-acetic acid, ester sulfoxide with a sulfonic acid and heat to provide a 3-acylamido-4-(2-oxaalkylthio)azetidin-2-one ester which on treatment with sulfuryl chloride affords a reaction product mixture that is then reduced with an organo tin hydride, e.g., tri(n-butyl)tin hydride, to the product. N-Deacylation of the 3-acylamido group followed by acylation with the 3-acyl portion of FR 1923, deblocking of the amino-protecting group and deesterification affords FR 1923.

    摘要翻译: 1- [α-(羧基)-4-羟基或被保护的羟基苄基] -3-酰基氨基吖丁啶-2-酮酯的方法,用于制备抗生素FR1923的有用中间体,包括2-酰基-3,3 - 二烷基-7-氧代-α-[4-(保护的 - 羟基苯基)-4-硫杂-2,6-二氮杂双环[3.2.0]庚烷-6-乙酸,与磺酸并加热的酯亚砜, 3-酰基酰胺基-4-(2-氧杂烷硫基)氮杂环丁-2-酮,其用硫酰氯处理得到反应产物混合物,然后用有机锡氢化物如三(正丁基)氢化锡还原至 产物,3-酰基酰氨基的N-去酰化,随后用FR 1923的3-酰基部分酰化,氨基保护基团的解封端和脱酯化,得到FR 1923。

    Hydroxy substituted phenylglycylamido-3-heterocyclic thiomethyl
cephalosporins
    5.
    发明授权
    Hydroxy substituted phenylglycylamido-3-heterocyclic thiomethyl cephalosporins 失效
    羟基取代的苯基甘氨酰氨基-3-杂环硫代甲基头孢菌素

    公开(公告)号:US3946003A

    公开(公告)日:1976-03-23

    申请号:US498886

    申请日:1974-08-20

    IPC分类号: C07D501/32 C07D501/36

    CPC分类号: C07D501/36

    摘要: 7-(4-Hydroxyphenylglycylamido)-3-(1-methyl-1H-tetrazolyl-5-thiomethyl)-3-cephem-4-carboxylic acid, 7-(4-hydroxyphenylglycylamido)-3-(5-methyl-1,3,4-thiadiazolyl-2-thiomethyl)-3-cephem-4-carboxylic acid, the corresponding 3-hydroxy isomers and the pharmaceutically acceptable, non-toxic salts thereof are orally effective antibiotics exhibiting high blood levels.

    摘要翻译: 7-(4-羟基苯基甘氨酰胺基)-3-(1-甲基-1H-四唑-5-硫甲基)-3-头孢烯-4-羧酸,7-(4-羟基苯基甘氨酰胺基)-3-(5-甲基-1- 3,4-二噻唑基-2-硫代胞嘧啶基)-3-头孢烯-4-羧酸,相应的3-羟基异构体及其药学上可接受的无毒盐是具有高血药浓度的口服有效的抗生素。

    3.beta.-succinimidoazetidinones as chiral intermediates
    8.
    发明授权
    3.beta.-succinimidoazetidinones as chiral intermediates 失效
    3β-琥珀酰亚氨基氮杂环丁酮作为手性中间体

    公开(公告)号:US4734498A

    公开(公告)日:1988-03-29

    申请号:US884124

    申请日:1986-07-10

    摘要: 3.beta.-Substituted succinimido)azetidinones represented by the formula ##STR1## wherein R and R.sub.1 are e.g. C.sub.1 -C.sub.5 alkanoyloxy, benzoyloxy, substituted benzoyloxy, or benzyloxy, or one of R and R.sub.1 is hydrogen and the other is as defined above; R.sub.2 is C.sub.1 -C.sub.4 alkoxycarbonyl or an arylvinyl group e.g. styrryl or 2-furylvinyl; and R.sub.3 is e.g. protected-carboxymethyl, or an NH protecting group; are provided via stereoselective cycloaddition of imines with chiral auxiliary 3,4-disubstituted succinimidoacetyl chlorides. The chiral auxiliary e.g., 3S,4S-dibenzoyloxy-and 3S,4S-diacetoxysuccinimidoacetyl chloride, is obtained from tartaric acid via anhydride and imide formation with retention of chirality. The chiral azetidinones obtained are useful intermediates to .beta.-lactam antibacterial compounds.

    摘要翻译: 3β-取代的琥珀酰亚胺基)氮杂环丁酮,其中R和R 1是例如。 C1-C5烷酰氧基,苯甲酰氧基,取代的苯甲酰氧基或苄氧基,或R和R1中的一个是氢,另一个如上所定义; R2是C1-C4烷氧基羰基或芳基乙烯基,例如 苯乙烯基或2-呋喃基乙烯基; 和R3是例如。 保护羧甲基或NH保护基; 通过亚胺与手性辅助3,4-二取代的琥珀酰亚胺基乙酰氯的立体选择性环加成来提供。 手性辅助剂例如3S,4S-二苯甲酰氧基和3S,4S-二乙酰氧基琥珀酰亚胺基乙酰氯通过酸酐和酰亚胺形成由酒石酸获得,并保持手性。 获得的手性氮杂环丁酮是β-内酰胺抗菌化合物的有用中间体。